Cheynne, WY, USA
Blockchain
Kraken is a leading digital asset platform known for its strong security practices, deep liquidity, and wide ranging support for both fiat and cryptocurrency pairs. It offers services not only for retail users but also institutional clients, including derivatives, staking, OTC trading, and more advanced features for high‑volume traders. Kraken has made regulatory compliance and transparency cornerstones of its operations, being one of the first exchanges to provide Proof of Reserves audits. Over the years it has expanded globally, serving clients in dozens of countries, and supports trading in hundreds of digital assets plus multiple fiat currencies including USD, EUR, GBP, CAD, and others. Kraken has also broadened its product set beyond simple exchange functions, offering institutional‑grade tools and services to better meet the needs of more sophisticated market participants.
San Francisco, CA, USA
MedTech
Everside Health Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Everside Health’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Everside Health’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Everside Health is working toward a Marketing Authorization Application for selinexor to be reviewed by the European Medicines Agency.
A supplemental New Drug Application was recently accepted by the FDA seeking accelerated approval for selinexor as a new treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In addition to single-agent and combination activity against
a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune
disease, certain viruses and wound-healing. Everside Health has several investigational programs in clinical or preclinical development.
San Francisco, CA, USA
AI Application
Veem is a fintech / payments platform specializing in simplifying cross-border payments for small and medium businesses. It abstracts away the complexity of foreign exchange, international rails, and settlement, offering a user-friendly interface for sending, tracking, and reconciling payments globally. The company integrates with accounting software (e.g. QuickBooks) and offers APIs so platforms can embed this capability. Over time, Veem is pushing further into infrastructure — building robust routing, FX hedging, liquidity management, and compliance modules so that its payments backbone is scalable, resilient, and competitive with legacy SWIFT or bank-based corridors.
Oncology
Toronto, ON, Canada
Arcellx is a clinical-stage biotech company developing novel engineered immune cell therapies to treat cancer. Their technology leverages a proprietary D-Domain scaffold (a small binding domain) which is coupled with other platforms (including ddCAR and ARC-SparX) to design potent, modular chimeric antigen receptor (CAR) cell therapies. The company’s pipeline spans multiple hematologic and solid tumor indications — including multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and potentialy solid tumors.
Infrastructure
Cato Networks is a cloud-native cybersecurity and networking platform provider that pioneered the Secure Access Service Edge (SASE) model, combining networking, security, and threat detection into a unified global service. Their solution enables organizations to securely connect any user, site, or application — anywhere — using a globally distributed backbone and zero-trust access policies, removing the need for disjointed point solutions. Over the years, Cato has demonstrated impressive success with strong year-over-year revenue growth and now serves thousands of enterprises across multiple continents. The company continues to innovate by integrating advanced technologies, including AI-driven security features, to stay ahead of emerging threats. With its unified architecture, high growth momentum, and continuous product development, Cato has grown to become a recognized leader in transforming how enterprise networking and security converge in the cloud era.
Indianapolis, IN, USA
Health Services
Marathon Health is a U.S. based healthcare provider of direct primary care services, specializing in employer-sponsored and union-sponsored health solutions. Marathon offers a patient-centered, AI enabled, value-based healthcare model designed to improve outcomes and reduce costs. Their services encompass primary and preventive care, mental health support, musculoskeletal care, occupational health, medication management, and population health management.
Berlin, Germany
Oncology
T-Knife Therapeutics is a clinical stage biotech company focused on T cell receptor engineered T cell therapies (TCR-Ts), which aim to treat solid tumor cancers using engineered T cells capable of recognizing tumor antigens via TCRs. Their lead program, TK-6302, is a PRAME (Preferentially Expressed Antigen in Melanoma)-targeting TCR-T, enhanced with “armoring” modifications to improve T cell fitness, persistence, and ability to function in immunosuppressive tumor microenvironments.
Berlin, Germany
Oncology
Parabilis Medicines is a clinical-stage biotech company developing extraordinary medicines by targeting previously “undruggable” proteins in cancer. The company’s proprietary Helicon™ discovery platform engineers stabilized, cell-penetrant helical peptides capable of modulating intracellular protein-protein interactions, performing targeted protein degradation, or serving as radioligand therapies. Their lead program, FOG-001, is a first-in-class inhibitor of the interaction between β-catenin and TCF4, currently in clinical trial for solid tumours.
Wädenswil, Switzerland
Immunology
GlycoEra is a preclinical stage biotech company pioneering the development of extracellular protein degraders for the treatment of autoimmune diseases. Their proprietary platform, called the CustomGlycan™ platform, enables the design of biologics that can selectively bind, target, and degrade circulating disease-causing proteins (e.g., autoantibodies) rather than simply inhibiting them. Their lead program, GE8820, is designed to target pathogenic IgG4 autoantibodies for the treatment of a variety of autoimmune conditions.
Cambridge, MA, USA
Oncology
Nested is a clinical stage biotech company focused on advancing precision oncology medicine by finding new driver mutations to reach a broader group of patients. Their proprietary platform (“DeCRYPTion Platform”) combines genomics, structural biology, computational chemistry, proteomics and AI to map mutational clusters onto the structural proteome and identify novel “druggable” pockets. Their lead program, NST‑628, is a fully brain-penetrant small molecule molecular glue targeting pan-RAF/MEK, aiming to provide with deep and durable response.
Basel, Switzerland
Oncology/Autoimmune
RedRidge Bio is a biotech company developing transformative therapies for cancer and autoimmune diseases.
Needham, MA, USA
Health Services
Knownwell is a U.S. based healthcare service company focused on weight-inclusive primary care and metabolic health. Knownwell offers both in-person and virtual care, providing a non-stigmatizing, clinically driven health home for patients with overweight or obesity. It integrates primary care, nutrition counseling, behavioral health, and metabolic health services (including GLP-1 prescribing where appropriate), delivering better care and lasting outcome. Knownwell accepts most major insurance plans including Medicare.
Portland, OR, USA
Cybersecurity
Eclypsium is a cybersecurity company that secures the foundation of enterprise IT infrastructure by focusing on firmware, hardware, and software components often invisible to traditional security tools. Its platform provides continuous monitoring, threat detection, and vulnerability remediation across the full device lifecycle—from the supply chain to production. One of its standout products, Automata, uses binary reverse‑engineering and ML‑assisted analysis to uncover previously unknown firmware vulnerabilities and backdoors. Eclypsium has proven traction with both government agencies and large enterprise customers, especially in sectors where device integrity and regulatory compliance are mission‑critical. With rising threats targeting supply chains, firmware, and hardware components, Eclypsium is positioned as a provider of “below‑the‑OS” visibility and defense against stealthy, persistent attacks
Chicago, IL, USA
Cybersecurity
Empirical Security builds AI‑driven vulnerability prioritization and risk modeling tools that are tailored to each enterprise’s context. They maintain global models (e.g. EPSS) and also create localized models using a client’s telemetry and environment to surface the highest-risk vulnerabilities. Their approach aims to reduce alert noise and improve decision-making in security operations.
Munich, Germany
AI/AI Infrastructure
Pandas AI, developed by Sinaptik, is a Python library and platform that extends Pandas (and related data structures) with conversational, natural language querying capabilities. Users can ask questions of their data (CSV, SQL tables, DataFrames) in plain English and receive insights, visualizations, or computed results without writing explicit code. It supports multiple LLM backends and can be deployed in notebooks, apps, or as server components, enabling both exploratory analysis for data scientists and data interrogation by non‑technical users. The project is actively evolving, adding features like pipeline abstractions, synthetic data generation, multi-turn conversation, and context preservation.
Bellevue, WA, USA
AI Infrastructure
The next-generation foundation AI agent using reinforcement learning.
Sunnyvale, CA, USA
Infrastructure
Rafay delivers a Kubernetes operations and infrastructure automation platform that helps enterprises manage and scale applications, especially AI/ML workloads, across clouds, data centers, and edge environments. The company provides environment templates, policy-based cluster orchestration, and governance controls (RBAC, audit trails) tailored for AI, including GPU integrations and generative AI frameworks (e.g. Bedrock, ChatGPT, MLflow, Kubeflow) as part of its GenAI templates. Rafay’s value lies in enabling platform engineering teams to offer self-service infrastructure (clusters, environments) to developers and data scientists, while maintaining consistency, security, and observability over AI/ML workloads. They also support multi-tenant, chargeback/showback capabilities, GPU metrics, and lifecycle management across distributed AI deployments.
San Fransisco, CA, USA
AI Application
High-performance AI search and matching for semi-structured data, with customized vectorization.
San Fransisco, CA, USA
AI Application
Your virtual AI/ML Engineer.
San Fransisco, CA, USA
AI Application
Automate browser-based workflows with AI, killing last-gen RPAs.
San Fransisco, CA, USA
AI Application
The first agent-mobile device interface.
San Fransisco, CA, USA
AI Application
Revolutionizes 3D generation with sparse representation and watertight mesh creation. Text-to-3D and image-to-3D synthesis at 1024³ resolution with its 4× faster training speed.
